Loop and thiazide diuretics are clinically useful to induce negative sodium balance. However, with chronic treatment, their effects tend to be blunted since the kidney adapts to diuretics. Molecular identification of the renal ion transporters has provided us with a new understanding of the mechanisms of intrarenal adaptation to diuretics at molecular levels. In the kidney, loop and thiazide diuretics are secreted from the proximal tubule via the organic anion transporter-1 (OAT1) and exert their diuretic action by binding to the Na-K-2Cl cotransporter type 2 (NKCC2) in the thick ascending limb and the Na-Cl cotransporter (NCC) in the distal convoluted tubule, respectively. Recent studies in animal models suggest that abundance of these ion transporters is affected by longterm diuretic administration. Downstream from the primary site of diuretic action, an increase in epithelial Na + channel (ENaC) abundance is induced by chronic furosemide or hydrochlorothiazide treatment. This adaptation is consistent with previous reports showing cellular hypertrophy and increased Na + absorption in distal tubular segments. The abundance of NKCC2 and NCC is increased by furosemide and hydrochlorothiazide, respectively. This compensatory upregulation suggests that either diuretic may activate the ion transporter within the primary site of action. In the proximal tubule, the abundance of OAT1 is increased by chronic treatment with furosemide or hydrochlorothiazide. This upregulation of OAT1 seems to be induced by substrate stimulation, lessening diuretic tolerance associated with long-term diuretic use.
Introduction
Diuretics are widely used in clinical medicine in the treatment of hypertension and other disorders that are characterized by accumulation of fluid in the interstitial or extracellular compartments. However, some patients become resistant to their effects. There have been several potential explanations for this observation, and mechanisms of renal adaptation to diuretics may account for those of diuretic tolerance [1] . One possible explanation is altered expression or activity of the renal Na + transporters, which act as the targets for diuretics. Another possibility is the compensatory responses occurring downstream from the primary site of diuretic action.
Molecular cloning of each of the renal Na + transporters has been accomplished, and expression of these transporters in tubular cells has allowed the definition of the properties of each of the specific transporters. The molecular identification of these transporters has also led to the development of antibodies specific for each of the transporters [2, 3] , enabling us to study at a protein level the regulation of the renal Na + transporters and the potential mechanisms of intrarenal adaptation to long-term diuretic use.
This review provides a brief overview of the major renal Na + transporters which act as the targets for diuretics, and then focuses on the renal adaptation of ion transporters to chronic diuretic treatment. These intrarenal mechanisms of adaptation underlie diuretic tolerance or resistance. The terms 'diuretic tolerance' and 'diuretic resistance' are used interchangeably because both represent the waning natriuretic effect, but I prefer 'diuretic tolerance' to 'diuretic resistance' to indicate physiological adaptation of normal kidneys to the diuretic use. Diuretic resistance in a strict sense is a phenomenon occurring in pathophysiologic conditions such as renal failure, nephrotic syndrome, congestive heart failure and liver cirrhosis. The mechanisms of diuretic resistance in these clinical settings can be explained by altered pharmacokinetics and pharmacodynamics [4, 5] and will not be covered in this review.
Major Renal Na + Transporters along the Distal Tubular Segments
The Na-K-2Cl Cotransporters The Na-K-2Cl, K-Cl, and Na-Cl cotransporters (NCC) comprise a superfamily of cation-chloride cotransporters [6] . Two distinct Na-K-2Cl cotransporter (NKCC) genes (SLC12A1 and SLC12A2) have been cloned, and they are responsible for transporter protein NKCC2 (or BSC1) and NKCC1 (or BSC2), respectively. Both are expressed in the mammalian kidney and are large proteins with a core molecular weight of about 120-150 kDa. Each also has a similar overall topology with a large hydrophobic central region of 12 membrane-crossing helices (M1-M12) flanked by large hydrophilic regions that appear to face the interior of the cell. Sugar residues are linked to an extracellular loop between M7 and M8 making these cotransporters glycoproteins and increasing their apparent molecular weight on Western blotting to 150-195 kDa [7] .
The NKCC2 gene, SLC12A1, is predominantly, if not exclusively, expressed in the thick ascending limb [8] [9] [10] and macula densa cells [11] . Polyclonal antibodies directed against the rat NKCC2 protein showed cotransporter-specific labeling only on apical membranes of the thick ascending limb and macula densa cells in the rat kidney [12] [13] [14] . Interestingly, nitric oxide synthase is coexpressed in the macula densa, suggesting that NKCC2 may serve as the sensor of luminal chloride delivery to the macula densa and that nitric oxide is a mediator or modulator of subsequent effects in concert with or through locally synthesized prostanoids [15] .
Ion transport function and diuretic sensitivities of NKCC2 have been determined using Xenopus laevis oocytes injected with synthetic messenger RNA (cRNA) made from this cotransporter complementary DNA [10] . Cotransporter cRNA-injected oocytes exhibited high levels of potassium-and chloride-dependent 22 Na + uptake. This sodium uptake was specifically inhibited by bumetanide, while thiazides such as hydrochlorothiazide and metolazone had no effects. Thus, NKCC2 is kidney specific and encodes the apical 'loop' diuretic-sensitive NKCC that mediates NaCl reabsorption in the thick ascending limb.
Studies in animal models have explored ways in which abundance of the NKCC2 might be altered. Vasopressin, either exogenously or endogenously, increases abundance of the NKCC2 [16] . Studies with G s · knockout mice indicate that this effect of vasopressin is through G s ·, presumably to increase cAMP, which then increases transporter abundance via a cAMP-regulatory element of the NKCC2 gene [17] . The net effect would be an increase in solute reabsorption at the thick limb, contributing to sodium retention and increasing the driving force for water reabsorption.
On the other hand, vasopressin regulates collecting duct water channel aquaporin-2 (AQP2) on both shortterm and long-term bases [18] . The short-term regulation involves apical trafficking of AQP2 from intracellular cytoplasmic vesicles [19] , and the long-term regulation is derived from altered abundance of AQP2 [20] . A previous in vitro microperfused tubule study has shown that vasopressin acutely stimulates NaCl transport in mouse medullary thick ascending limbs [21] , and a recent functional expression study using X. laevis oocytes has demonstrated that cAMP can stimulate membrane trafficking of NKCC2 [22] . Thus, there is a possibility that, similarly to AQP2, NKCC2 may be regulated via apical membrane trafficking by short-term vasopressin stimulation.
The abundance of the NKCC2 is also influenced by renal prostanoids, wherein PGE 2 decreases its expression [23] . PGE 2 activates the EP3 receptor, causing decreases in cAMP via G i ; through the cAMP-regulatory element, abundance of the transporter decreases. Such an effect would decrease the driving force for water reabsorption and thereby diminish the hydrosmotic response to vasopressin, a well-known effect of PGE 2 [24] . This role of PGE 2 could also explain the effect of nonsteroidal antiinflammatory drugs in causing sodium and water retention, an effect that has been shown in clinical studies to occur anatomically at the thick ascending limb [25] .
The NKCC1 gene, SLC12A2, was originally cloned from the shark rectal gland [26] , and then subsequently from humans [27] and mice [28] . Heterologous expression of the human NKCC1 in mammalian cells gives rise to bumetanide-sensitive Na-K-2Cl transport [26] . Messenger RNA and the cotransporter protein encoded by the NKCC1 gene are expressed in many different tissues and cells, including the kidney [28] .
Antibodies raised against NKCC1 revealed cotransporter expression in two distinct regions of the kidney [29, 30] . In the cortex, the cotransporter was localized to renin-containing granular cells and vascular smooth muscle cells of afferent arteriole, glomerulus, and extraglomerular mesangium. Given this cortical pattern of expression of the NKCC1 and the macula densa expression of the NKCC2, it is not surprising that furosemide both blocks tubuloglomerular feedback and modulates renin secretion.
The NKCC1 protein is also expressed on basolateral membranes of type A intercalated cells of the rat collecting duct [30] and on basolateral membranes along the terminal third of the mouse papillary collecting duct [29] . The potential effect of 'loop' diuretics on acid secretion and/or NaCl transport by the papillary collecting duct is at present unclear.
The Na-Cl Cotransporter
The NCC was originally cloned from the flounder urinary bladder [31] and subsequently in the mammalian kidney [32, 33] . The NCC transcripts are expressed predominantly in the kidney, where they are restricted to distal convoluted tubule cells in the rat [34, 35] and rabbit kidney [36] . Polyclonal antibodies raised against the rat NCC show that the protein is limited to the apical surface of distal convoluted tubule cells [34, 37] .
The NCC is a relatively large glycoprotein with a core molecular weight of about 110 kDa, and the glycosylated mature protein has an apparent molecular weight of about 150 kDa on immunoblotting [34, 37] . This cotransporter protein has an overall topology that is similar to the NKCC. The two N-linked glycosylation sites in the large extracellular loop between M 7 and M8 [32] are essential for efficient function and surface expression of the cotransporter, and elimination of glycosylation improves the access of thiazide diuretics to their binding site [38] .
The NCC protein has been established as an important target for regulation by the steroid hormones aldosterone [37] and estradiol [39] . The finding of strong upregulation of NCC abundance in response to the mineralocorticoid aldosterone emphasizes that aldosterone stimulates sodium absorption throughout the post-macula densa portion of the nephron, not just in the collecting duct (as previously believed). Dietary salt restriction mimicked the effect of aldosterone to increase NCC abundance [37] . However, dietary salt restriction had little or no effect on NCC mRNA expression in the renal cortex [40] , suggesting that aldosterone-mediated effects on NCC protein abundance occur by mechanisms such as the regulation of NCC degradation or the regulation of NCC translation.
The Epithelial Na + Channel
The amiloride-sensitive epithelial Na + channel (ENaC) is composed of three homologous subunits [41] : ·-ENaC (SCNN1A), ß-ENaC (SCNN1B), and Á-ENaC (SCNN1G) assembled as a heterotetramer of ·2:ß1:Á1 [42, 43] . All subunit proteins contain a large, highly glycosylated extracellular loop that is located between two transmembrane segments. The N-and C-terminal segments are cytoplasmic and contain potential regulatory segments that may modulate channel activity [44] .
Although Na + currents are generated when only the · subunit is expressed in Xenopus oocytes, the current is greatly enhanced by coexpression of ·-, ß-, and Á-ENaC. Xenopus oocytes expressing all three subunits produce currents that are Na + selective and exhibit properties consistent with the function of ENaC in native tissues [41] . The Na + conductance generated upon expression of all three subunits in Xenopus oocytes is sensitive to both amiloride and triamterene.
Polyclonal antibodies raised against the ·, ß, and Á subunits of ENaC show channel proteins at the apical membrane of epithelial cells in connecting tubules, cortical collecting ducts, outer medullary collecting ducts, and inner medullary collecting ducts [44] [45] [46] [47] . In the collecting duct, the subunits are expressed in principal, but not intercalated cells, which correlated with the known physiological expression of amiloride-sensitive Na + channels in theses nephron segments. Regulation of ENaC activity in the Kim collecting duct and connecting tubule involves several control processes: (1) control of subunit abundance as seen in response to aldosterone or vasopressin [45, 48] ; (2) regulated trafficking [47, 49] , and (3) posttranslational modifications, such as methylation [50] .
Molecular Mechanisms of the Action of Loop and Thiazide Diuretics
The clinically useful and potent distal-acting diuretics enhance urinary NaCl excretion by specific inhibition of distinct sodium transport processes in the loop of Henle and distal nephron. Whereas the bulk of NaCl is reabsorbed in the proximal tubule, the fine tuning of salt excretion is accompanied by regulating the reabsorption of NaCl in the thick ascending limb of Henle (15-20%), the distal convoluted tubule (5-7%), and the collecting ducts (2-3%). Therefore, the clinically useful diuretics reduce salt reabsorption in these distal nephron segments.
The molecular cloning of the distal diuretic-sensitive Na + transporters has significantly enhanced our understanding of the mechanism of action of each class of diuretics and has clearly defined the specific transporter protein that is the target for each of these diuretics. Loop diuretics such as furosemide and bumetanide reduce sodium transport in the thick ascending limb of the loop of Henle by inhibiting the NKCC2. Thiazide diuretics decrease salt reabsorption in distal convoluted tubule by inhibiting the NCC.
Loop Diuretics Inhibiting the NKCC2
The most potent clinically useful diuretics are those inhibiting NaCl reabsorption in the thick ascending limb of the loop of Henle. These drugs are often referred to as 'loop' diuretics since their major effect is on the thick ascending limb of the loop of Henle, or as 'high ceiling' diuretics because of their potent natriuretic effects [4, 5] . The most widely used loop diuretics are furosemide, bumetanide, torasemide, and ethacrynic acid.
Loop diuretics like furosemide appear to inhibit the NKCC2 by binding at or near to the second Cl -site on the cotransporter protein [51] . The ion-and diuretic-binding regions of the NKCC2 cotransporter proteins appear to be confined to the amino acid residues making up the central hydrophobic domain that contains the 12 transmembrane segments [52] . NKCC1 and NKCC2 exhibit differences, however, in their ion-binding affinities (K m values) and their bumetanide inhibition constants (K i values). NKCC2 has a 4-fold higher bumetanide affinity, making the renal thick ascending limb cotransporter more sensitive to inhibition by loop diuretics [53] .
Thiazide Diuretics Inhibiting the NCC
The NCC in the distal convoluted tubule is the target site for clinically useful thiazide diuretics like hydrochlorothiazide. Ion transport function and diuretic sensitivities of the flounder urinary bladder [31] and the rat kidney [10] NCCs were characterized in X. laevis oocytes. Cotransporter RNA-injected oocytes exhibited chloride-dependent tracer sodium uptake. This sodium uptake was specifically inhibited by thiazides, e.g. hydrochlorothiazide or metolazone, whereas the loop diuretic bumetanide had no effect. Thiazide diuretics appear to bind at or near the Cl -site on the NCC protein in a competitive fashion [54] . Recently, however, Monroy et al. [55] has reported that both ion binding sites alter thiazide-mediated inhibition of transport. Thus, the thiazide-binding site may be either shared or modified by both Na + and Cl -.
Diuretic Tolerance
There are two forms of diuretic tolerance [4] . Shortterm tolerance refers to a decrease in the response to a diuretic after the first dose has been administered. This can be prevented by restoring diuretic-induced loss of volume [56] [57] [58] , implying that volume loss per se is the stimulus for whatever effectors are responsible. However, the mechanism by which short-term tolerance occurs is unclear. Potential mediators include angiotensin II, sympathetic nervous system activation, or both [5] , because the secretion of angiotensin II and norepinephrine varies inversely with the effective circulating volume. Physiological doses of angiotensin II stimulate volume and solute transport in the proximal tubule independent of changes in the glomerular filtration rate [59] , and the main target of angiotensin II in the proximal tubule is the type 3 Na + / H + exchanger (NHE3) [60, 61] . Thus, increasing the NHE3 activity probably via the traffic of the NHE3 protein between a cytoplasmic compartment and the apical membrane [62] may contribute to the short-term diuretic tolerance. However, neither the inhibition of angiotensinconverting enzyme nor adrenergic blockade, separately or together, consistently prevents it [63] [64] [65] . Thus, other as yet unidentified mechanisms must also be involved.
Long-term diuretic tolerance occurs with chronic administration. Recent experimental work using animal models has indicated how kidneys adapt to chronic diuretic treatment at ion transporter levels [66, 67] . The 
Compensatory Upregulation of Na + Transporters Downstream from the Primary Site of Diuretic Action
With long-term administration of a thiazide or loop diuretic, the solute that escapes from the primary site of diuretic action floods more distal regions of the nephron.
Increased sodium delivery to the distal nephron may result in enhanced sodium absorption downstream from the distal site of diuretic action. In furosemide-infused, volume-replaced rats, Stanton and Kaissling [68, 69] demonstrated an increase in distal Na + absorption accompanied by an increase in epithelial cell volume of the distal convoluted tubule, connecting tubule and collecting duct. Consistent with this general hypertropic effect of chronic furosemide infusion, the total amount of protein in cortical homogenates [66] and DNA synthesis in distal segments downstream of the thick ascending limb [70] were increased in furosemide-infused rats. The mechanism by which increased exposure to solute causes hypertrophy of distal nephron segments is unknown, but the increase in sodium concentration within renal epithelial cells may elicit a 'mitogen-like' effect and promote cell growth [71] .
With the advent of molecular cloning of the distal renal diuretic-sensitive sodium transporters, our understanding of the mechanism of long-term diuretic tolerance was greatly enhanced. Loop diuretic infusion increases the number of thiazide-sensitive transporters [72] , the rate of thiazide-sensitive sodium transport [73] , the expression of NCC mRNA [74] and the activity of Na-K-ATPase along the distal tubule [75] . Abdallah et al. [76] reported that furosemide infusion increased NCC protein abundance, but this effect was blocked by spironolactone, suggesting that the response was dependent on a rise in plasma aldosterone concentration.
Blocking ion transport at the primary site of diuretic action increases Na + delivery to the connecting tubule and collecting duct, where the ENaC constitutes the rate-limiting step for Na + reabsorption. Na et al. [66] showed that the abundance of ENaC was increased in response to chronic infusion of either furosemide or hydrochlorothiazide ( fig. 1) , consistent with previous reports showing increased Na + absorption in these segments [69, 77] . This upregulation of ENaC should have a crucial influence upon final urinary sodium excretion because ENaC constitutes the rate-limiting step for sodium reabsorption in the connecting tubule and collecting duct in the rat kidney [78] . Regarding the mechanism of altered ENaC subunit protein abundance, regulation of mRNA levels [79, 80] and regulation of ENaC protein half-life [81] [82] [83] have been described. Although changes in transporter abundance are by no means the only way in which transport capacity of renal tubule cells is regulated, the increase in ENaC abundance that Na et al. [66] have observed is likely to represent adaptive responses to allow for the conservation of Na + in response to diuretic administration. Con-sequently, sodium that escapes from the primary site of diuretic action is reabsorbed at more distal sites, decreasing overall diuresis.
Diuretic-Induced Activation of Target Transporters within the Primary Site of Diuretic Action
One mechanism by which diuretic drugs may increase the tendency for NaCl retention directly involves diuretic-induced activation of ion transporters within the diuretic-sensitive nephron segment [1] . This sounds paradoxical, considering the inhibiting attribute of diuretics at their target sites. However, it has been reported that the secretory isoform of the loop diuretic-sensitive NKCC in the dogfish shark rectal gland is activated by decreases in intracellular chloride concentration [84] . Because loop diuretics reduce the chloride concentration in cells of the thick ascending limb, loop diuretics should leave transporters in an activated state once diuretic concentrations decline.
Consistent with the above notion, Na et al. [66] showed that furosemide induced an increased abundance of NKCC2, while hydrochlorothiazide induced an increased abundance of NCC ( fig. 2) . This may represent a compensatory response, contributing to diuretic tolerance. Similarly, ENaC protein abundance was also found to be increased by chronic administration of amiloride, showing another example of diuretic-induced activation of Na + transporters within the diuretic-sensitive nephron segment ( fig. 3) . Consistent with the effect of hydrochlorothiazide administration on NCC abundance, the binding density of [ 3 H]metolazone, an indirect measure of NCC abundance, was previously demonstrated to be increased by chronic hydrochlorothiazide infusion [72, 85] despite a decrease in NaCl transport capacity in distal convoluted tubules [86] .
Substrate Stimulation of Organic Anion Transporter-1 in the Proximal Tubule
The proximal tubular secretion of loop diuretics and thiazides is critical for their diuretic action because it is through this mechanism that they gain access to luminal tubular target sites in effective amounts [87] . Loop diuretics and thiazides are weak organic acids, having a common chemical characteristic (sulfonamide diuretics), and hence are secreted by the renal organic anion transporter (OAT) system from the blood into the tubular lumen to reach their principal sites of action [87] . Among many OAT molecules which have recently been cloned, OAT1 seems to be the most important in the renal tubular secretion of both thiazides and loop diuretics. Previous approaches using the rat or human OAT1-expressing X. laevis oocyte system have shown that OAT1, function- ing as a para-aminohippurate (PAH)/dicarboxylate antiporter, mediates proximal tubular secretion of these diuretics. Bartel et al. [88] have shown that thiazides and loop diuretics inhibit in vitro tubular uptake of PAH in single S2 segments from the proximal tubule of rabbit kidney. Uwai et al. [89] also reported that PAH uptake by OAT1-expressing X. laevis oocytes was inhibited in the presence of thiazide and loop diuretics. Recently, Kim et al. [67] demonstrated that both furosemide and hydrochlorothiazide induced a powerful diuresis in parallel with increases in OAT1 protein abundance in rat kidney, supporting a role for OAT1 in the renal tubular secretion of thiazides and loop diuretics at the protein level. This effect appeared to result from the diuretic agent itself, because sucrose water loading, which increased urine volume as well, failed to increase OAT1 protein abundance. Besides, in response to chronic diuretic infusion, the increase in OAT1 protein abundance was not accompanied by any change in Na-K-ATPase protein abundance, despite the possibility that the activity of OAT1 may change in parallel with that of Na-K-ATPase. In the organic anion transport pathways, OAT1 is indirectly linked to Na-K-ATPase in the basolateral membrane of proximal tubule cells, as shown in figure 4 . The selective increase in OAT1 protein suggests that furosemide and hydrochlorothiazide may have a direct stimulatory effect on OAT1 protein synthesis (fig. 4) . As a potential mechanism of OAT1 upregulation induced by chronic diuretic administration, substrate stimulation is conceivable [67] .
Substrate stimulation is one of the important factors regulating OAT1 [90] . Hirsch and Hook [91, 92] were the first to demonstrate that prior injection of penicillin (twice daily for 3 days) in 2-week-old rabbit pups led to an increase in the uptake of PAH by kidney cortical slices. This phenomenon was thought to be a result of increased biosynthesis of transport proteins, since pre-treatment with penicillin leads to greater incorporation of leucine and glutamine into the slice proteins and to enhancement of protein content in the microsomal fraction, whereas administration of the protein synthesis inhibitor cycloheximide to nursing rats prevents substrate stimulation of PAH uptake by renal slices [93] . Thus, substrate stimulation occurs to cause an increase in the synthesis of the transporter protein involved in the secretion of organic compounds.
What is the clinical implication of this upregulation of OAT1 in long-term diuretic use? A potential role of interaction of diuretics with the renal organic anion transport system can be speculated; upregulation of OAT1 will enhance the delivery of diuretics to the target sites. The diuretic tolerance exerted by upregulation of distal renal Na + transporters may be mitigated by the OAT1 upregulation.
Conclusion
The molecular identification of renal ion transporters has provided a new understanding of the mechanisms responsible for diuretic tolerance. Chronic administration of thiazides or loop diuretics upregulates renal ion transporters, that is, OAT1 at the site of secretion, NKCC2 or NCC within the primary site of action, and ENaC downstream from the primary site of action ( fig. 5 ). It should be clear that the functional integrity of these ion transporters determines the degree of diuretic response. Upregulation of distal renal Na + transporters would cause diuretic tolerance by enhancing Na + reabsorption, while substrate stimulation of OAT1 may lessen diuretic tolerance by increasing delivery of diuretics to the target transporters.
